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In addition, ACD showed a high anti-leukemia effect in the BNML rat acute myelocytic leukemia model, 2 while at the same time ACD has only minor toxicity to normal pluripotent hemopoietic stem cells (HSC) as we have previously shown. 3 ACD is currently being evaluated in phase 1 clinical trials. Despite successful remission induction and consolidation treatment of acute leukemia with cytostatic agents, the majority of AML cases eventually develop a leukemia relapse. This implies that the leukemic cells have either developed drug resistance or that they already had a natural resistance and were selected out by the treatment. 4 Here, we report on the absence of cross-resistance between ACD and daunomycin (Dauno), cytosine arabinoside (Ara-C) or cyclophosphamide (CP) using resistant sublines for each of these drugs in the BNML leukemia model in the rat. [5] [6] [7] Normal BN/HsdRij rats (SPF quality) were injected on day 0 with 1 × 10 7 cells i.v. from either the BNML parental cell line BNML/P or with the BNML/Dauno-R, BNML/CP-R or BNML/Ara-C-R sublines. ACD treatment was started on day 7 after leukemia transfer for the BNML/CPR, BNML/Ara-C-R and the BNML/P groups and on day 5 for the BNML/Ara-C-R group because this line showed slightly more rapid growth kinetics. Thus, the leukemic cell load was comparable for each of the drug-resistant BNML variants. ACD was administered intragastrically, as a suspension in methyl cellulose, in a dose of 11.85 mg/kg/day for 5 consecutive days. For each resistant BNML subtype an untreated group of rats carrying the same cell line served as control. All experimental groups consisted of eight rats. To calculate the anti-leukemic effect of ACD the increase in survival time (IST) of treated animals vs that of the Table 1 Efficacy of acetyldinaline treatment in the daunomycineresistant, Ara-C resistant or cyclophosphamide resistant BNML sublines compared to the BNML parental cell line
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Median . In all groups all rats died from leukemia relapse. In Table 1 
Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan

TO THE EDITOR
An increasing proportion of patients with myelodysplastic syndromes (MDS) have had previous exposure to chemotherapeutic agents, classically alkylating drugs, but recently also purine analogues, anthracyclines and epipodophyllotoxins. [1] [2] [3] [4] Most cases follow treatment after a median interval of 4-5 years and are associated with prominent dysplasia, mild to marked reticular fibrosis and cytogenetic These results show that the sublines of the BNML rat leukemia model that acquired resistance for either Dauno, Ara-C or CP during repeated in vivo administration of the respective drugs retained the sensitivity for ACD. During the treatment of AML the leukemic cells often acquire resistance to the frequently used drugs Dauno, Ara-C or CP. The exact mode of action of ACD is not yet known although there are reports that it affects intracellular amino acid transport thus interfering with protein metabolism, DNA synthesis and cell proliferation. 8 On the basis of the preclinical study reported here it is concluded that the mechanisms involved in the resistance to Dauno, Ara-C and CP, do not effect the susceptibility of the resistant cells for ACD. Clinical evaluation of ACD in acute leukemia, especially in leukemia patients resistant to those cytostatic drugs, is warranted.
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Utrecht, The Netherlands abnormalities in chromosomes 5 and 7. Busulfan, as an alkylating agent, has a known leukemogenic potential. Evidence is suggestive that the increasing duration of chemotherapy and the cumulative dose of the drug influence the development of secondary MDS (s-MDS) and increase the risk of leukemogenesis. 1, 3 We report a patient with chronic myeloid leukemia (CML) who had received busulfan over a 2-month period and developed dysplastic features including sideroblastic erythropoiesis shortly after the drug was discontinued.
A 70-year-old woman presented with paleness, weight loss and a markedly enlarged spleen. Laboratory evaluation revealed hemoglobin 7.0 g/dl, WBC 250 × 10 9 /l (blasts 5%, myelocytes 1%, metamyelocytes 2%, bands 16%, segmented neutrophils 53%, eosinophils 10%, lymphocytes 6%, monocytes 7%) and platelets 930 × 10
